Page 12 - Sanket Koul

Nifty Realty falls 1.22% as developers fear missing FY26 sales guidance

Demand slowdown, buyers getting priced out of affordable housing, reflecting in FY26 numbers

Educational institutions' income to rise 11-13% in FY26, FY27: Crisil

The report added that operating margins are expected to remain steady at 27 to 28 per cent as these institutions will incur higher staff salaries and other related costs

Bhumika Realty raises ₹170 cr to fund mixed-use project in Faridabad

Bhumika Realty raises ₹170 crore from Aditya Birla Sun Life AMC-BGO credit platform to fund its ₹700-crore mixed-use project in Faridabad

Suraksha Group completes 6K homes at Jaypee's stalled Wish Town projects

Suraksha Group completes nearly 6,000 homes across 63 towers at Noida's Wish Town, securing OCs for over 3,100 units after Jaypee Infratech takeover

Branded residences market likely to grow 60% by 2027 on global push

India's branded residences boom is gathering pace, with global luxury names and rising wealth set to drive a 60% jump in projects by 2027

Signature Global Q3 sales bookings fall 27% on lower housing sales

Signature Global's Q3 FY26 sales bookings fell 27% to ₹2,020 crore as housing demand softened and delayed project launches limited festive-season momentum

Rabies vaccine sales hit 5-year high in 2025 amid rise in dog bite cases

According to data from market research firm Pharmarack, the combined number of ARV and immunoglobulin vaccines sold in 2025 reached 8,510,000 units - the highest in five years

Surge in non-NCR regions pushes 19% rise in new project registration in UP

Uttar Pradesh saw a 19% rise in real estate project registrations in 2025, with non-NCR cities driving more balanced growth, UP Rera data showed

Budget 2026-27: Health sector seeks tax relief, rationalised rates

Ahead of Budget 2026-27, healthcare, medtech and pharma firms seek tax relief, higher R&D incentives and stronger support for preventive care and domestic manufacturing

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

NITI Aayog proposes Hudco & NHB-anchored fund for affordable rental housing

10-15% EWS/LIG reservation in all housing projects proposed, along with tax exemption for developer profits on affordable housing

DoP invites proposals under two schemes to cut medtech import reliance

With India importing about 70 per cent of its medical devices, the Department of Pharmaceuticals has invited proposals under two sub-schemes to reduce import dependence and support clinical studies

Govt bans sale, use of oral formulations of nimesulide for human use

The Union Health Ministry has prohibited manufacture and sale of oral nimesulide formulations above 100 mg for human use, citing liver toxicity risks and acting on ICMR and DTAB recommendations

Centre to restrict cough syrup sales by unlicensed village pharmacists

Draft amendments propose removing "syrup" from Schedule K exemptions, tightening over-the-counter sales in small villages after Madhya Pradesh cough syrup deaths

Intas, IntegriMedical sign pact to launch needle-free IVF injectors

Intas has signed an exclusive agreement with SII-backed IntegriMedical to deploy needle-free injection systems across IVF clinics, targeting an all-India rollout by Q1FY26.

Strong demand, premium pricing brings non- NCR developers to Gurugram

Industry experts agree that Gurugram's position as the corporate and commercial hub of NCR is a key draw

Health ministry unlikely to extend Schedule M GMP deadline for MSME pharma

The health ministry is unlikely to extend the revised Schedule M GMP deadline for MSME drugmakers beyond December 31, 2025, as it consults states ahead of risk-based inspections

Gaurs Group raises ₹440 crore via NCDs to fund realty, expansion plans

Delhi NCR-based Gaurs Group raised Rs 440 crore via NCDs subscribed by three mutual funds to fund land acquisition, project execution and refinancing, with debentures to list on NSE

Fake rabies vaccine row: IIL says counterfeit batch no longer available

Indian Immunologicals Limited said the issue flagged by Australian authorities relates to a single counterfeit batch identified earlier and does not warrant a blanket warning against the vaccine